The DepoVax™ platform is a lipid depot-based vaccine enhancement and delivery technology. DepoVax enhances vaccine performance, be it a cellular or humoral immune response. Click here to learn more. Partnership, collaboration and licensing opportunities are available through our DepoVax Challenge OR to advance Immunovaccine’s vaccine products.
1. DepoVax® Challenge – Our DepoVax Challenge is a research partnership where you send your antigens to Immunovaccine and we incorporate them into our DepoVax® platform. We then send the new vaccine formulation back to you for testing in your validated models to compare the results head-to-head with your previous formulations. This may yield interesting data to advance your vaccine product and / or create next generation products for your company. For more information on the DepoVax challenge click here.
2. DPX-0907 – DPX-0907 is a therapeutic cancer vaccine candidate containing seven antigens indicated for breast, ovarian and prostate cancer. These seven antigens are involved in major cancer cell pathways and are present on the cancer cell surface. DPX-0907 has completed a Phase I clinical trial at five U.S. sites and is Phase II ready. The positive safety results of the clinical trial demonstrate:
We are seeking partners to develop DPX-0907 for follow-on clinical trials.
For more information on DPX-0907 click here.
3. DPX-Survivac – DPX-Survivac is a survivin-based therapeutic cancer vaccine. As survivin is a critical molecule for cancer cell survival and highly associated with many types of tumor cells, it is considered a universal cancer antigen. While DPX-Survivac has broad market potential to target at least nine different cancers, Immunovaccine is developing DPX-Survivac to treat ovarian cancer for initial Phase I / II clinical trials. We are presently seeking partners to develop DPX-Survivac for additional indications.
For more information on DPX-Survivac click here.
For partnering opportunities, please contact:
Vicki Morgan, Director of Business Development 902-492-1819, ext. 4 or vmorgan@imvaccine.com
